Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China

Authors: Rena Maimaiti, Yuexin Zhang, Kejun Pan, Peierdun Mijiti, Maimaitiali Wubili, Maimaitijiang Musa, Rune Andersson

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Tuberculosis and HIV co-epidemics are problems in many parts of the world. Xinjiang is a high tuberculosis and HIV prevalence area in China. We aimed to investigate the prevalence and cure rate of tuberculosis among HIV positive patients in Xinjiang.

Methods

In a retrospective study between 2006 and 2011, clinical and laboratory data on 333 patients with HIV and tuberculosis were compared to 2668 patients with HIV only. There were 31 HIV positive patients with no data on tuberculosis.

Results

The prevalence of tuberculosis co-infection among the HIV positive patients was 11% (95% CI 10–12%), significantly higher than the national figure in China of 2%. In most cases HIV was diagnosed late, with advanced immunodeficiency. The use of isoniazid preventive therapy was only 57.9% in patients without tuberculosis who fulfilled the criteria for receiving this prevention. The cure rate one year after diagnosis was 69.2%, which was lower than the officially reported 91.4% in all tuberculosis cases in Xinjiang in 2011. The hazard of not surviving over the five years was significantly higher in patients with HIV + tuberculosis compared to HIV only after adjusting for sex and Intravenous drug use with HR = 1.84 (95% CI 1.43-2.35; p < 0.0001).

Conclusions

The prevalence of tuberculosis among HIV positive patients in Xinjiang was higher than in China taken as a whole, and HIV was diagnosed late, with underuse of isoniazid preventive therapy. The low cure rate and reduced survival can be due to late diagnosis of HIV and no testing for antibiotic resistance, together with insufficient control of adherence to the treatment regimens for tuberculosis and HIV.
Literature
1.
go back to reference Harrington M. From HIV, to tuberculosis and back again: a tale of activism in 2 pandemics. Clin Infect Dis. 2010;50:S260–6.CrossRefPubMed Harrington M. From HIV, to tuberculosis and back again: a tale of activism in 2 pandemics. Clin Infect Dis. 2010;50:S260–6.CrossRefPubMed
2.
go back to reference Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis. 2007;196 Suppl 1:S1–3.CrossRefPubMed Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis. 2007;196 Suppl 1:S1–3.CrossRefPubMed
5.
go back to reference López-Gatell H, Cole SR, Hessol NA, French AL, Greenblatt RM, Landesman S, et al. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol. 2007;165(10):1134–42.CrossRefPubMed López-Gatell H, Cole SR, Hessol NA, French AL, Greenblatt RM, Landesman S, et al. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol. 2007;165(10):1134–42.CrossRefPubMed
6.
go back to reference Meya DB, McAdam KP. The TB pandemic: an old problem seeking new solutions. J Intern Med. 2007;261:309–29.CrossRefPubMed Meya DB, McAdam KP. The TB pandemic: an old problem seeking new solutions. J Intern Med. 2007;261:309–29.CrossRefPubMed
7.
go back to reference Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS. 2000;14 Suppl 3:S47–56.PubMed Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS. 2000;14 Suppl 3:S47–56.PubMed
9.
go back to reference Reddy KP, Brady MF, Gilman RH, et al. Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. Clin Infect Dis. 2010;50(7):988–96. doi:10.1086/651081.CrossRefPubMedPubMedCentral Reddy KP, Brady MF, Gilman RH, et al. Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. Clin Infect Dis. 2010;50(7):988–96. doi:10.​1086/​651081.CrossRefPubMedPubMedCentral
10.
go back to reference Aït-Khaled N, Alarcon E, Bissell K, et al. Isoniazid preventive therapy for people living with HIV : public health challenges and implementation issues. Int J Tuberc Lung Dis. 2009;13(8):927–35.PubMed Aït-Khaled N, Alarcon E, Bissell K, et al. Isoniazid preventive therapy for people living with HIV : public health challenges and implementation issues. Int J Tuberc Lung Dis. 2009;13(8):927–35.PubMed
11.
go back to reference Palmieri F, Girardi E, Pellicelli AM, et al. Pulmonary tuberculosis in HIV-infected patients presenting with normal chest radiograph and negative sputum smear. Infection. 2002;30:68–74.CrossRefPubMed Palmieri F, Girardi E, Pellicelli AM, et al. Pulmonary tuberculosis in HIV-infected patients presenting with normal chest radiograph and negative sputum smear. Infection. 2002;30:68–74.CrossRefPubMed
12.
go back to reference Yuan X. The impact of the implementation of the DOTS strategy to TB control in Shihezi region. Endem Dis Bull. 2010;25(3):44–5. Yuan X. The impact of the implementation of the DOTS strategy to TB control in Shihezi region. Endem Dis Bull. 2010;25(3):44–5.
14.
go back to reference Yuehua L, Wu G, Mahemuti M. Evaluation of Xinjiang fifth round of global fund tuberculosis and AIDS co-infection control project. China tuberculosis control collaboration. Lancet. 2010;32(11):767–9. Yuehua L, Wu G, Mahemuti M. Evaluation of Xinjiang fifth round of global fund tuberculosis and AIDS co-infection control project. China tuberculosis control collaboration. Lancet. 2010;32(11):767–9.
15.
go back to reference Yuehua L, Wang X, Xue F, et al. Current status of HIV infection in patients with tuberculosis in Xinjiang. Dis Prev Control Bull. 2014;29(3):19–21. Yuehua L, Wang X, Xue F, et al. Current status of HIV infection in patients with tuberculosis in Xinjiang. Dis Prev Control Bull. 2014;29(3):19–21.
16.
go back to reference Mingjian NI, Xueling CHEN, Jin CHEN, Wen HE, Wei LIU. HIV infection prevalence factors among drug users in Xinjiang. China J Public Health. 2013;29(8):1101–3. Mingjian NI, Xueling CHEN, Jin CHEN, Wen HE, Wei LIU. HIV infection prevalence factors among drug users in Xinjiang. China J Public Health. 2013;29(8):1101–3.
17.
go back to reference Chinese society of tuberculosis, Chinese Medical Association. Tuberculosis diagnosis and treatment guidelines. Chinese J Tuberc Respir Dis. 2001;24(1):70–4. Chinese society of tuberculosis, Chinese Medical Association. Tuberculosis diagnosis and treatment guidelines. Chinese J Tuberc Respir Dis. 2001;24(1):70–4.
18.
go back to reference Piot A, Chaulet P. Implementing the WHO stop TB strategy: a handbook for national tuberculosis control programmes. Geneva: World Health Organization; 2008. Piot A, Chaulet P. Implementing the WHO stop TB strategy: a handbook for national tuberculosis control programmes. Geneva: World Health Organization; 2008.
19.
go back to reference Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis. 2001;33:1762–9.CrossRefPubMed Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis. 2001;33:1762–9.CrossRefPubMed
20.
go back to reference Munseri PJ, Bakari M, Pallangyo K, Sandstrom E. Tuberculosis in HIV voluntary counselling and testing centres in Dar es Salaam, Tanzania. Scand J Infect Dis. 2010;42:767–74.CrossRefPubMed Munseri PJ, Bakari M, Pallangyo K, Sandstrom E. Tuberculosis in HIV voluntary counselling and testing centres in Dar es Salaam, Tanzania. Scand J Infect Dis. 2010;42:767–74.CrossRefPubMed
23.
go back to reference Balcha TT, Winqvist N, Sturegård E, Skogmar S, Reepalu A, Jemal ZH, et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres. Trop Med Int Health. 2014;19(6):734–42.CrossRefPubMed Balcha TT, Winqvist N, Sturegård E, Skogmar S, Reepalu A, Jemal ZH, et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres. Trop Med Int Health. 2014;19(6):734–42.CrossRefPubMed
24.
go back to reference Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993–2006. Clin Infect Dis. 2009;49:1350–7.CrossRefPubMed Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993–2006. Clin Infect Dis. 2009;49:1350–7.CrossRefPubMed
26.
go back to reference Takarinda KC, Harries AD, Srinath S, Mutasa-Apollo T, Charles S, Mugurungi O. Treatment outcome of adult patients with recurrent tuberculosis in relation to HIV status in Zimbabwe: a retrospective record review. BMC Public Health. 2012;12:124.CrossRefPubMedPubMedCentral Takarinda KC, Harries AD, Srinath S, Mutasa-Apollo T, Charles S, Mugurungi O. Treatment outcome of adult patients with recurrent tuberculosis in relation to HIV status in Zimbabwe: a retrospective record review. BMC Public Health. 2012;12:124.CrossRefPubMedPubMedCentral
27.
go back to reference Wang CS, Chen HC, Yang CJ, Wang WY, Chong IW, Hwang JJ, et al. The impact of age on the demographic, clinical, radiographic characteristics and treatment outcomes of pulmonary tuberculosis patients in Taiwan. Infection. 2008;36:335–40.CrossRefPubMed Wang CS, Chen HC, Yang CJ, Wang WY, Chong IW, Hwang JJ, et al. The impact of age on the demographic, clinical, radiographic characteristics and treatment outcomes of pulmonary tuberculosis patients in Taiwan. Infection. 2008;36:335–40.CrossRefPubMed
28.
go back to reference Leeds IL, Magee MJ, Kurbatova EV, del Rio C, Blumberg HM, Leonard MK, et al. Site of extrapulmonary tuberculosis is associated with HIV infection. CID. 2012;55(1):75–81.CrossRef Leeds IL, Magee MJ, Kurbatova EV, del Rio C, Blumberg HM, Leonard MK, et al. Site of extrapulmonary tuberculosis is associated with HIV infection. CID. 2012;55(1):75–81.CrossRef
31.
go back to reference Yuding Z, Qin F, Ke T, Congcong Z, Honghu S, Tao L, et al. The population structure of drug-resistant mycobacterium tuberculosis clinical isolates from Sichuan in China. Infect Genet Evol. 2012;12:718–24.CrossRef Yuding Z, Qin F, Ke T, Congcong Z, Honghu S, Tao L, et al. The population structure of drug-resistant mycobacterium tuberculosis clinical isolates from Sichuan in China. Infect Genet Evol. 2012;12:718–24.CrossRef
32.
go back to reference Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of anti-tuberculosis drug resistance 2002–07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet. 2009;373:1861–73.CrossRefPubMed Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of anti-tuberculosis drug resistance 2002–07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet. 2009;373:1861–73.CrossRefPubMed
33.
go back to reference Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–15.CrossRefPubMedPubMedCentral Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–15.CrossRefPubMedPubMedCentral
34.
go back to reference Taye T. Balcha, Erik Sturegård, Niclas Winqvist, Sten Skogmar, Anton Reepalu, Zelalem Habtamu Jemal, et al. Intensified Tuberculosis Case-Finding in HIV-Positive Adults Managed at Ethiopian Health Centers: Diagnostic Yield of Xpert MTB/RIF Compared with Smear Microscopy and Liquid Culture. PLoS ONE. 2014; 9(1): e85478. doi:10.1371. journal.pone.0085478 Taye T. Balcha, Erik Sturegård, Niclas Winqvist, Sten Skogmar, Anton Reepalu, Zelalem Habtamu Jemal, et al. Intensified Tuberculosis Case-Finding in HIV-Positive Adults Managed at Ethiopian Health Centers: Diagnostic Yield of Xpert MTB/RIF Compared with Smear Microscopy and Liquid Culture. PLoS ONE. 2014; 9(1): e85478. doi:10.1371. journal.pone.0085478
35.
go back to reference Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153–61.CrossRefPubMed Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153–61.CrossRefPubMed
36.
go back to reference Faustini A, Hall AJ, Perucci CA. Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J. 2005;26:503–10.CrossRefPubMed Faustini A, Hall AJ, Perucci CA. Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J. 2005;26:503–10.CrossRefPubMed
37.
go back to reference Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008;46:1844–51.CrossRefPubMedPubMedCentral Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008;46:1844–51.CrossRefPubMedPubMedCentral
38.
go back to reference Kritski AL, de Jesus LS R, Andrade MK, Werneck-Barroso E, Vieira MA, Haffner A, et al. Retreatment tuberculosis cases factors associated with drug resistance and adverse outcomes. Chest. 1997;111:1162–7.CrossRefPubMed Kritski AL, de Jesus LS R, Andrade MK, Werneck-Barroso E, Vieira MA, Haffner A, et al. Retreatment tuberculosis cases factors associated with drug resistance and adverse outcomes. Chest. 1997;111:1162–7.CrossRefPubMed
39.
go back to reference Maimaiti R, Zhang Y, Pan K, Maimaiti W, Andersson R. Frequent coinfection with hepatitis among HIV-positive patients in Urumqi, China. J Int Assoc Phys AIDS Care (JIAPAC). 2013;12(1):58–61. Maimaiti R, Zhang Y, Pan K, Maimaiti W, Andersson R. Frequent coinfection with hepatitis among HIV-positive patients in Urumqi, China. J Int Assoc Phys AIDS Care (JIAPAC). 2013;12(1):58–61.
40.
go back to reference Yang X, Yuan Y, Pang Y, Wang B, Bai Y, Wang Y, et al. The Burden of MDR/XDR Tuberculosis in Coastal Plains Population of China. PLoS ONE. 2015; 10(2): e0117361. doi:10.1371/journal. pone.0117361. Yang X, Yuan Y, Pang Y, Wang B, Bai Y, Wang Y, et al. The Burden of MDR/XDR Tuberculosis in Coastal Plains Population of China. PLoS ONE. 2015; 10(2): e0117361. doi:10.1371/journal. pone.0117361.
42.
go back to reference Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, An-chalee A, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807. doi:10.1056/NEJMoa1506816.CrossRefPubMed Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, An-chalee A, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807. doi:10.​1056/​NEJMoa1506816.CrossRefPubMed
Metadata
Title
High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China
Authors
Rena Maimaiti
Yuexin Zhang
Kejun Pan
Peierdun Mijiti
Maimaitiali Wubili
Maimaitijiang Musa
Rune Andersson
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-2152-4

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue